摘要
目的:探讨伊立替康(CPT-11)联合卡培他滨一线治疗进展期胃癌的疗效、不良反应及疾病进展时间(TTP)。方法:进展期胃癌患者132例,平均分为治疗组66例,给予CPT-11联合卡培他滨化疗;对照组66例,给予FOLFOX4方案化疗,均为一线治疗。治疗组每2个周期后评价疗效,对照组每3个周期后评价疗效,观察两组的客观疗效、不良反应及TTP。结果:治疗组有效率及疾病控制率分别为62.12%(41/66)、90.91%(60/66),高于对照组的42.42%(28/66)、75.76%(50/66),两组有效率比较差异有统计学意义(χ2=5.131 8,P=0.023 5),疾病控制率比较差异有统计学意义,χ2=5.454 5,P=0.019 5;TTP治疗组为8.2个月(6～26个月),对照组为5.8个月(4～20个月),两组比较差异有统计学意义,P=0.028 3;不良反应治疗组主要为消化道反应、手足综合征和血液学毒性,对照组主要为消化道反应、神经毒性、血液学毒性,两组多为Ⅰ～Ⅱ度。结论:CPT-11联合卡培他滨一线治疗进展期胃癌,与FOLFOX4方案比较,疗效显著,TTP延长,毒副反应可耐受,安全性高,且用药方便,值得临床广泛推广应用。
OBJECTIVE： To observe the efficacy, safety and median time to progression （TTP） of irinotecan （CPT-11） combined with capecitabine in first line treatment of patients with advanced gastric cancer. METHODS：Totally 132 patients with advanced gas- tric cancer were randomly divided into 2 groups, experimental group （n= 66） given irinotecan combined with capecitabine, and control group （n=66） given FOLFOX 4. They were assessed on the basis after 2 and 3cycles respectively. RESULTS： Totally 132 patients were assessable to observe the efficacy and safety and MST. The response rate was 62. 12% （41/66） in the experimental group and 42.42%（28/66） in the control group. The disease control rate was 90.91%（60/66） in the experimental group and 75.76% （50/66） in the control group. There was significant difference between the two groups （χ^2=5.131 8, P=0.023 5;χ^2=5.454 5, P=0.019 5）. Median time to progression （TTP） was 8. 2 months （6 to 26 months） in the experimental group and 5.8 months （4 to 20 months） in the control group. There was significant difference between the two groups （P=0. 028 3）. The major adverse reactions in the experimental group were digestive tract effect, acute choline syndrome, delayed diarrhea, hand-foot syndrome and blood toxicity. The major adverse reactions in the control group were digestive tract effect, nervous and blood toxicity. Most of them were Ⅰ/Ⅱ degree. CONCLUSIONS： Irinotecan combined with capecitabine in line-1 treatment of patients with advanced gastric cancer can get better efficacy with tolerated adverse reactions and convenient medication. It can be extensively used.
出处
《中华肿瘤防治杂志》
CAS
2011年第9期710-712,共3页
Chinese Journal of Cancer Prevention and Treatment
基金
衡水市科技局2008年科研课题立项项目(08008Z)
关键词
伊立替康
卡培他滨
胃肿瘤/药物疗法
药物疗法
联合
irinoteeon
capecitabine
stomach neoplasms/drug therapy
drug therapy, combination
